Each tablet contains Torsemide 10 mg and Spironolactone 25 mg.

Torsinex Plus Tablets combine the potent loop diuretic Torsemide with the potassium-sparing diuretic Spironolactone to provide effective management of fluid retention while minimizing potassium loss. The combination promotes the elimination of excess sodium and water, reduces edema associated with heart failure and liver cirrhosis, and helps maintain potassium balance, making it suitable for patients at risk of hypokalemia.

Torsinex Plus Tablets are indicated for the treatment of edema associated with congestive heart failure, liver cirrhosis, and hypokalemia. The combination helps relieve fluid overload while preserving serum potassium levels.

Torsemide is a loop diuretic that acts within the thick ascending limb of the loop of Henle, where it inhibits the Na⁺/K⁺/2Cl⁻ cotransporter. This action increases the urinary excretion of sodium, chloride, and water, thereby reducing extracellular fluid volume and relieving edema. Spironolactone is an aldosterone receptor antagonist that acts at the aldosterone-dependent sodium-potassium exchange sites in the distal convoluted renal tubule. It promotes the excretion of sodium and water while conserving potassium, thereby complementing the diuretic effect of Torsemide and helping prevent hypokalemia.

The recommended dose is one tablet once daily, or as directed by the physician.

Torsinex Plus Tablets are contraindicated in patients with known hypersensitivity to Torsemide, Spironolactone, or any component of the formulation. Torsemide is contraindicated in patients with anuria and hepatic coma. Spironolactone is contraindicated in patients with anuria, acute renal insufficiency, significant impairment of renal excretory function, or hyperkalemia.